Monday, June 7, 2021
4:00 p.m. AST
On Zoom
Join us for the next webinar as part of the KAUST Smart-Health Initiative (SHI) Seminar Series.
The role of biobanking in precision medicine
By Professor Peter Metrakos, Associate Professor of Surgery Pathology and Associate Professor in Anatomy and Cell Biology at McGill University.
About the speaker
Dr. Peter Metrakos, is Associate Professor of Surgery, Pathology and Associate Professor in Anatomy and Cell Biology at McGill University. He is also Director of the Multi-Organ Transplant Program and Director of Hepatopancreatobiliary Surgery at the McGill University Health Center.
Dr. Metrakos graduated in General Surgery from McGill University Faculty of Medicine, where he also completed a three-year Basic Science Fellowship in the Department of Experimental Surgery focusing on the physiology of the pancreas and cellular transplantation.
His research interests include the role and interaction of chemotherapy and liver resection in the management of colorectal cancer liver metastases (CRCLM). Other research interests are in Hepatocellular carcinoma (HCC), neuroendocrine tumours and targeted therapies. Dr. Metrakos also studies the role of ischemia/reperfusion of non-alcoholic fatty liver disease in liver transplantation and liver resections. In addition, Dr. Meterakos is interested in basic/translational and clinical research that focuses on systems medicine and personalized care of patients.
Taking an innovative approach to the management of CRCLM, he was amongst the first in North America to use neoadjuvant chemotherapy and to apply portal vein embolization and staged resection strategies to convert patients to a resectable state. This has improved patient outcomes and we have published and presented some of the largest series of patients undergoing these procedures in the world. A specialized HPB Tumour Board was created under Dr. Metrakos Chairmanship to help care and manage the treatment complex diseases. Dr. Metrakos has established a Liver Disease Biobank at McGill University that has been certified through the CTRNET and is a member of ISBER and ESBB.
This biobank’s structure is amongst the most modern and includes a complete legal and ethical framework with a Tissue Access Committee. The Liver Disease Biobank at McGill University has become a resource for the McGill cancer research community and community in Montreal (McGill, UQAM, and Université de Montréal).
